The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 18 of the 57 sources its claims cite were checked for support.
Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial
Open accessPublished version of a preprint
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric disorders. However, the exact mechanism of action and why effects can take several weeks to manifest is not clear. The hypothesis of neuroplasticity is supported by preclinical studies, but the evidence in humans is limited. Here, we investigate the effects of the SSRI escitalopram on presynaptic density as a proxy for synaptic plasticity. In a double-blind placebo-controlled study (NCT04239339), 32 healthy participants with no history of psychiatric or cognitive disorders were randomized to receive daily oral dosing of either 20 mg escitalopram ( n = 17) or a placebo ( n = 15). After an intervention period of 3–5 weeks, participants underwent a [ 11 C]UCB-J PET scan (29 with full arterial input function) to quantify synaptic vesicle glycoprotein 2A (SV2A) density in the hippocampus and the neocortex. Whereas we find no statistically significant group difference in SV2A binding after an average of 29 (range: 24–38) days of intervention, our secondary analyses show a time-dependent effect of escitalopram on cerebral SV2A binding with positive associations between [ 11 C]UCB-J binding and duration of escitalopram intervention. Our findings suggest that brain synaptic plasticity evolves over 3–5 weeks in healthy humans following daily intake of escitalopram. This is the first in vivo evidence to support the hypothesis of neuroplasticity as a mechanism of action for SSRIs in humans and it offers a plausible biological explanation for the delayed treatment response commonly observed in patients treated with SSRIs. While replication is warranted, these results have important implications for the design of future clinical studies investigating the neurobiological effects of SSRIs.
Overview
CoChat Summary
TL;DR
In a double-blind placebo-controlled trial in 32 healthy adults, 3–5 weeks of escitalopram did not significantly change [11C]UCB-J PET SV2A binding in the hippocampus or neocortex versus placebo. Secondary analyses found a time-dependent positive association between escitalopram intervention duration and neocortical SV2A binding, suggesting delayed synaptic plasticity.
Key findings
- Primary group comparison showed no statistically significant difference after an average of 29 days: hippocampus VT was 15.1 (2.2) vs. 14.3 (1.9) mL/cm3 for escitalopram vs. placebo (Cohen’s d = 0.43, 95% CI [−0.36, 1.20], p = 0.26); neocortex VT was 18.3 (2.5) vs. 17.6 (2.0) mL/cm3 (d = 0.31, 95% CI [−0.47, 1.08], p = 0.41).
- Secondary duration analysis found a positive time-dependent effect in the escitalopram group: neocortex +0.41 mL/cm3 per day (rρ = 0.46, p = 0.016) vs. −0.12 mL/cm3 per day for placebo (rρ = −0.18, p = 0.38); hippocampus +0.25 mL/cm3 per day (rρ = 0.31, p = 0.11) vs. −0.14 mL/cm3 per day for placebo (rρ = −0.22, p = 0.26). With age, sex, and IQ covariates, effects were neocortex +0.47 mL/cm3 per day (rρ = 0.58, p = 0.003) and hippocampus +0.30 mL/cm3 per day (rρ = 0.40, p = 0.048).
- No association was found between s-escitalopram concentration and [11C]UCB-J VT: neocortex +0.81 mL/cm3 per log[ng/L] (rρ = 0.18, p = 0.48); hippocampus +0.39 mL/cm3 per log[ng/L] (rρ = 0.10, p = 0.70).
- Exploratory analyses found no significant escitalopram effects on hippocampus volume or cortical thickness.
Methods
- Double-blind, semi-randomized, placebo-controlled study in 32 healthy participants with no history of psychiatric or cognitive disorders; randomized to 20 mg escitalopram daily (n = 17) or placebo (n = 15), with a 3–5 week intervention and PET after an average of 29 days (range 24–38); 29 participants had a full arterial input function.
- [11C]UCB-J PET quantified SV2A binding using the one-tissue compartment model total volume of distribution (VT) in hippocampus and neocortex as primary outcome; SRTM2 BPND was a complementary analysis.
- Group comparisons used Welch two-sample t-tests and general linear models with age, sex, and IQ covariates; secondary analyses used linear regressions with group-by-intervention-duration interaction terms and Bonferroni-Holm correction.
Limitations
- Stated: no baseline [11C]UCB-J PET scans were included, so the study assumes no pre-intervention group differences in cerebral SV2A binding.
- Stated: the sample size was targeted to detect larger effect sizes, limiting detection of subtler differences and subgroup differences; replication is warranted, ideally with a longer intervention range and more subjects.
- Stated: SV2A is a proxy for presynaptic density, and changes could reflect number of vesicles per synapse or differential effects on excitatory and inhibitory synapses; the white matter reference region contains some SV2A and may overestimate the non-displaceable compartment.
- Evident from the text: the primary VT analysis included only 12 placebo participants with full arterial input function, reducing power, and the duration effect comes from a within-group secondary analysis over a relatively narrow 24–38 day range, so causality cannot be established from that association alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Effects of escitalopram on SV2A density. Comparison of [11C]UCB-J binding in healthy individuals following 3-5 weeks of intervention with escitalopram (n = 17) or placebo (n = 12). [11C]UCB-J total volume of distribution (VT) quantified using the 1TCM (n = 29).](https://figures.cochat.ai/paper-figures/668ce946719f437dbc4ca9c4013861ee/effects-of-escitalopram-on-synaptic-density-in-the-healthy-human-brain-a-figure-1.jpg)
![Fig. 2 Time-dependent effects of escitalopram on SV2A density. Relationship between [11C]UCB-J binding (VT) and the duration of the intervention for the placebo group (n = 12) and the escitalopram group (n = 17) in the neocortex (A) and the hippocampus (B). The shaded grey area represents the 95% CI.](https://figures.cochat.ai/paper-figures/c762141863b74f42ba63e7be8084507e/effects-of-escitalopram-on-synaptic-density-in-the-healthy-human-brain-a-figure-2.jpg)
Verification
Claims the paper makes
8 Valid · 2 Not valid · 23 Not checked · 52 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Delayed effects of the escitalopram intervention align with the clinical observations that when SSRIs are used for treating, e.g., depression, at least 2–4 weeks of treatment is required before effects on symptoms can be expected [29–31].”
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Discussion
What the sources say
- Not checked yetcites [29] Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharm. 2006;21:105–10. source
- Not checked yetcites [30] Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, et al. Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association. 2010. 3rd ed. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed Sep 6, 2022.
- Disputedcites [31] Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiat. 2006;63:1217–23. sourceExperimental — accuracy not yet measured
The paper describes a 2–3-week delay as conventional wisdom, but its Data Synthesis and Comment sections report improvement by the end of the first week. It explicitly says its findings exclude a required period of delay before treatment response. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“patients with severe depression have been found to have lower SV2A in the hippocampus and several neocortical regions [20].”
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Introduction
What the sources say
- Supportedcites [20] Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529. source
In Results > Group differences in synaptic density (page not provided), Fig. 2 reports lower SV2A density in the high-depressive-symptom group than in healthy controls, showing the hippocampus and two cortical regions: the dlPFC and ACC. The paper defines that group by a HAMD-17 score of at least 14. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PET studies on several neuropsychiatric disorders linked to synaptic dysfunction, including depression, have found lower cerebral SV2A density in patients compared to healthy individuals [17–22].”
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Introduction
What the sources say
- Partly supportedcites [17] Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin S, et al. Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2a positron emission tomographic imaging. Jama Neurol. 2018;75:1215. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report lower hippocampal SV2A binding on PET in participants with Alzheimer disease than in cognitively normal participants. This supports one disorder in the cited sentence, but the paper does not report PET findings for depression or several disorders. (LLM, conf=0.88)
- Not checked yetcites [18] Mecca AP, O’Dell RS, Chen M, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s disease. Alzheimer’s Dement. 2020;16:e037791. source
- Partly supportedcites [19] Mecca AP, O’Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, et al. Synaptic density and cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐J. Alzheimer’s Dement. 2022;18:2527–36. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) reports lower cerebral SV2A binding on PET in people with early Alzheimer’s disease than in cognitively normal participants. The paper does not report a comparable finding for depression or establish the claim across several neuropsychiatric disorders. (LLM, conf=0.87)
- Partly supportedcites [20] Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529. sourceExperimental — accuracy not yet measured
The Results (Group differences in synaptic density; page unavailable) report lower SV2A density than in healthy controls for the MDD-only group and for patients with high-severity depressive symptoms. The claim omits that the full clinical sample did not differ significantly from controls, nor did the low-severity or PTSD groups. This paper therefore supports the depression example, but not an unqualified reduction across patients with these disorders. (LLM, conf=0.88)
- Partly supportedcites [21] Onwordi EC, Halff EF, Whitehurst T, Mansur A, Cotel M-C, Wells L, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun. 2020;11:246. sourceExperimental — accuracy not yet measured
The Abstract reports lower [11C]UCB-J PET signal in the frontal and anterior cingulate cortices of patients with schizophrenia than in controls. The Discussion also describes PET evidence of synaptic reductions in epilepsy and Alzheimer’s disease, but describes only synaptic alterations in affective disorders; it does not establish lower SV2A density in depression versus healthy individuals. The depression portion of the sentence is therefore not supported by this source. (LLM, conf=0.84)
- Not checked yetcites [22] Radhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, et al. In vivo evidence of lower synaptic vesicle density in schizophrenia. Mol Psychiatr. 2021;26:7690–8. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The present study design also eliminates issues of long-term test-retest bias which has been reported to occur with [11C]UCB-J PET in some instances [59].”
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Discussion
What the sources say
- Supportedcites [59] Tuncel H, Boellaard R, Coomans EM, Vries EFde, Glaudemans AW, Feltes PK, et al. Kinetics and 28-day test–retest repeatability and reproducibility of [11C]UCB-J PET brain imaging. J Cereb Blood Metab. 2020;41:1338–50. source
The Discussion reports systematically lower retest values in this 28-day [11C]UCB-J PET study and specifies that the negative bias occurred in healthy controls, not Alzheimer’s disease patients. The citation supports the reported occurrence of bias; whether the citing authors’ own design eliminates it is their conclusion, not a finding attributed to this source. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neocortical subregions and subcortical regions were not included in our a priori hypothesis; none of these regions showed significant differences in [11C]UCB-J VT estimates between escitalopram and placebo groups as compared with Welch two-sample t-tests (Supplementary Table S1).”
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Results > Primary analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
28 more claims
Create a free account to see all 85 claims and to verify the 39 references still open.
- Probably not a substantial claim. 28
- It may state two separate claims as one. 33
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, given the evidence from both clinical and preclinical literature, it is very likely that SSRIs induce different synaptic patterns in patients and healthy subjects,11,27”
From Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of a secondary group-byintervention duration analysis revealed a significant timedependent group effect of escitalopram indicating higher [ 11 C] UCB-J V T values in hippocampus and neocortex as a function of increasing intervention duration in the escitalopram group, but not the placebo group.”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [161]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Positron emission tomography (PET) with [11C]UCB-J, a radioligand targeting Synaptic Vesicle 2A (SV2A), has emerged as a minimally invasive translational tool to study disease- or drug-associated changes in synaptic density.10−12”
From Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression (2025) · cites this paper as [11]
In the citing paper
“In humans, SV2A imaging has already been shown to be able to highlight abnormalities in synaptic density in patients with MDD13 and the effects of the SSRI escitalopram on synaptic density in healthy volunteers.11”
From Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression (2025) · cites this paper as [11]
In the citing paper
“Johansen and colleagues found evidence of the SSRI escitalopram increasing SV2A availability over a period of 3–5 weeks in healthy human subjects (Johansen et al., 2023).”
From A single subanaesthetic dose of the rapid-acting antidepressant S-ketamine raises presynaptic SV2A density in limbic regions of the Wistar Kyoto rat model of depression (2024) · cites this paper as Johansen et al., 2023
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Abstract
“average of 29 (range: 24–38) days of intervention”
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Results > Demographics and scan-related parameters
“Median [Min, Max] | 32.0 [22.0, 38.0] | 27.0 [24.0, 35.0]”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Methods > PET acquisition
“a 120 min PET scan was started at the time of intravenous [11C]UCB-J bolus injection”
§ Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial > Methods > PET acquisition
“reconstructed into 40 frames (8 × 15 s, 8 × 30 s, 4 × 60 s, 5 × 120 s, 10 × 300 s, 5 × 300 s)”
Citations
Cites
Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.021 · Cited by 9,526
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“Functionally, neuroplasticity can be thought of as the ability of the brain to change and adapt to physiological or psychological stimuli to uphold homeostasis [6].”
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
The developmental role of serotonin: news from mouse molecular genetics
Gaspar, P., Cases, O., & Maroteaux, L. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1256 · Cited by 1,297
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Sowell, E. R., Peterson, B. S., Kan, E., Woods, R. P., Yoshii, J., Bansal, R., Xu, D., Zhu, H., Thompson, P. M., & Toga, A. W. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhl066 · Cited by 695
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
How do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Research works printed but not linked: 2
- Reynolds CR, Kamphaus RW. Introduction to the Reynolds Intellectual Assessment Scales and the Reynolds Intellectual Screening Test. Contemporary intellectual assessment: theories, tests, and issues., New York, NY, US: The Guilford Press; 2005. p. 461–83.
- Lipsitz SR, Leong T, Ibrahim J, Lipshultz S. A partial correlation coefficient and coefficient of determination for multivariate normal repeated measures data. J R Stat Soc: Ser D (Stat). 2001;50:87–95.
Cited by
Page, C. E., Epperson, C. N., Novick, A. M., Duffy, K. A., & Thompson, S. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02625-2 · Cited by 80
“In people without depression, SSRI treatment increases synaptic density in the PFC and hippocampus after 5 weeks [80].”
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Corvo, C., Mendez-David, I., Goutal, S., Saba, W., Bottlaender, M., Caillé, F., Hen, R., Colle, R., Corruble, E., Tournier, N., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00621 · Cited by 7
Bærentzen, S. L., Waszkiewicz, A. L., Thomsen, M., Knudsen, C., Elfving, B., & Landau, A. M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104079 · Cited by 7
Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1
Metadata
- Authors
- Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., Vassilieva, A., Langley, C., Svarer, C., Stenbæk, D. S., Sahakian, B. J., & Knudsen, G. M.
- Affiliations
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Copenhagen University Hospital (DK)
- Innsbruck Medical University (AT)
- University of Cambridge (GB)
- Corresponding author
- Knudsen, Gitte M.
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2023-10
- Volume
- 28
- Issue
- 10
- Pages
- 4272-4279
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC10827655
- OpenAlex
- W4387451491
- Cited by
- 53
- References
- 62
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 20
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 8 d)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (acceptedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Funders
- Lundbeckfonden (R281-2018-131)
- Det Frie Forskningsråd (8020-00414B)
- Rigshospitalet (R216-A9684)
- Vetenskapsrådet (2021-00462)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- escitalopram, selective serotonin reuptake inhibitors, synaptic plasticity, presynaptic density, SV2A, hippocampus, neocortex, neuroplasticity, mechanism of action, delayed treatment response, healthy volunteers
- MeSH terms
- Escitalopram, Brain, Humans, Synapses, Citalopram, Selective Serotonin Reuptake Inhibitors, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial. https://app.cochat.ai/papers/10.1038/s41380-023-02285-8
- The paper
- Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., Vassilieva, A., Langley, C., Svarer, C., Stenbæk, D. S., Sahakian, B. J., & Knudsen, G. M. (2023). Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial. Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02285-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.